Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNA2 | P51530 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | CFTR | P13569 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GUSB | P08236 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 2/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19220850 | 0.90 | DNA2 (0.54) | DNA2CASP6CTDSP1CFTRMAPT | |
| SCHEMBL19220852 | 0.84 | DNA2 (0.71) | DNA2CASP6CTDSP1CFTRMAPT | |
| SCHEMBL2217097 | 0.80 | CFTR (0.74) | CFTRRORCMAOB | |
| SCHEMBL31078123 | 0.79 | P2RX1 (0.65) | MAPTLMNAMAPK1MEN1POLB | |
| SCHEMBL19220845 | 0.76 | DNA2 (0.72) | DNA2CASP6CTDSP1MAPTMAPK1 | |
| SCHEMBL19220853 | 0.75 | MAPT (0.50) | MAPTLMNAMAPK1MEN1POLB | |
| SCHEMBL6537720 | 0.75 | DNA2 (0.78) | DNA2CASP6CTDSP1MAPTMAPK1 | |
| SCHEMBL4334739 | 0.73 | DNA2 (1.00) | DNA2CASP6CTDSP1GUSB | |
| SCHEMBL396819 | 0.73 | CFTR (0.78) | CFTRMAOB | |
| SCHEMBL20153429 | 0.70 | DNA2 (0.62) | DNA2CASP6CTDSP1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2023-10-10 | — | — | US | disclosed |
| US-11198675-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200148645-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2020-05-14 | — | — | US | disclosed |
| US-10562856-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190092732-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2019-03-28 | — | — | US | disclosed |
| US-10173984-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134664-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2018-05-17 | — | — | US | disclosed |
| US-20180134664-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2018-05-17 | — | — | US | disclosed |
| US-9932310-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932310-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170226063-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2017-08-10 | — | — | US | disclosed |
| US-20170226063-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134664-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-10562856-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-20190092732-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-20200148645-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-20170226063-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-11198675-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-10173984-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.